Raymond James Financial Inc Protagonist Therapeutics, Inc Transaction History
Raymond James Financial Inc
- $264 Billion
- Q4 2024
A detailed history of Raymond James Financial Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Raymond James Financial Inc holds 303,313 shares of PTGX stock, worth $11.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
303,313Holding current value
$11.7 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
248Shares Held
57.2MCall Options Held
71.7KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$226 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$222 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$209 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$162 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$123 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.89B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...